Stock HCM HUTCHMED (CHINA) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Delayed London S.E.
Other stock markets
 16:22:44 02/05/2024 BST 		5-day change 1st Jan Change
309 GBX +3.00% Intraday chart for HUTCHMED (China) Limited +6.55% +9.19%
04-26 EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug MT
04-26 Hutchmed notes CHMP's positive opinion for fruiquintinib approval AN

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
AQ
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug
MT
Hutchmed notes CHMP's positive opinion for fruiquintinib approval
AN
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer
MT
Hutchmed to Present New Data at US Cancer Research Conference
MT
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024
CI
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
AQ
Hutchmed endometrial cancer treatment application accepted for review
AN
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination
MT
HSBC in special payout on Canada sale; Astra FDA win
AN
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
CI
Sector Update: Health Care Stocks Advance Premarket Thursday
MT
Hutchmed lung cancer treatment accepted for review in China
AN
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China
MT
JD Sports backs outlook; Spirent accepts new offer
AN
Hutchmed (China)'s NDA Application Accepted by Chinese Authorities
MT
HUTCHMED Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
CI
Hutchmed begins registration stage for sovleplenib phase 2/3 trial
AN
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
MT
Hutchmed (China) Initiates Phase II/III Clinical Trials for Autoimmune Disease Drug
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HCM Stock
  4. News HUTCHMED (China) Limited